Pradžia › Leukemija › Masčusetsas › Boston
Leukemija klinikiniai tyrimai Boston, MA
25 tyrimai dėl Leukemija ieško dalyvių vietose Boston ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Renkami dalyviai2 fazė
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Renkami dalyviai
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Renkami dalyviai3 fazė
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Renkami dalyviai2 fazė
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Renkami dalyviai1 fazė
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Renkami dalyviai1 fazė
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Renkami dalyviai1 fazė
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
Renkami dalyviai2 fazė
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Renkami dalyviai
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Renkami dalyviaiLaukiami sveiki savanoriai
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Renkami dalyviai1 fazė
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Renkami dalyviai1 fazė
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Renkami dalyviai1/2 fazė
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Renkami dalyviai1 fazė
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Renkami dalyviaiStebimasis tyrimas
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Renkami dalyviai2/3 fazė
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Renkami dalyviai
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
Renkami dalyviaiStebimasis tyrimas
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Renkami dalyviai1 fazė
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Renkami dalyviai1 fazė
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Renkami dalyviai1/2 fazė
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Renkami dalyviai1/2 fazė
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Renkami dalyviai1/2 fazė
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Renkami dalyviai
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Renkami dalyviai
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Leukemija tyrimai kituose miestuose
- Houston, TX28 tyrimai
- New York City, NY19 tyrimai
- Los Angeles, CA16 tyrimai
- Chicago, IL16 tyrimai
- Durham, NC13 tyrimai
- Baldwin Park, CA12 tyrimai
- Columbus, OH12 tyrimai
- Nashville, TN12 tyrimai
- Philadelphia, PA12 tyrimai
- Milwaukee, WI11 tyrimai
- Atlanta, GA11 tyrimai
- Seattle, WA11 tyrimai
Kiti tyrimai Boston
- Krūties vėžys111 tyrimai
- Nedidelinių ląstelių plaučių vėžys90 tyrimai
- Vėžys (visų tipų)86 tyrimai
- Storosios ir tiesiosios žarnos vėžys63 tyrimai
- Metastatinis vėžys63 tyrimai
- Plaučių vėžys62 tyrimai
- Kiaušidžių vėžys61 tyrimas
- Prostatos vėžys59 tyrimai
- Depresija52 tyrimai
- Endometrio vėžys50 tyrimai
- Širdies nepakankamumas44 tyrimai
- Ūmi mieloidinė leukemija44 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.